- Home
- PTHL vs IMNN Comparison
PTHL vs IMNN Comparison
Compare PTHL & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- IMNN
- Stock Information
- Founded
- PTHL 1998
- IMNN 1982
- Country
- PTHL China
- IMNN United States
- Employees
- PTHL N/A
- IMNN N/A
- Industry
- PTHL
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- IMNN Health Care
- Exchange
- PTHL Nasdaq
- IMNN Nasdaq
- Market Cap
- PTHL 13.5M
- IMNN 12.1M
- IPO Year
- PTHL 2024
- IMNN 1985
- Fundamental
- Price
- PTHL $1.02
- IMNN $5.76
- Analyst Decision
- PTHL
- IMNN Buy
- Analyst Count
- PTHL 0
- IMNN 2
- Target Price
- PTHL N/A
- IMNN $182.61
- AVG Volume (30 Days)
- PTHL 1.9M
- IMNN 59.7K
- Earning Date
- PTHL 01-01-0001
- IMNN 11-06-2025
- Dividend Yield
- PTHL N/A
- IMNN N/A
- EPS Growth
- PTHL N/A
- IMNN N/A
- EPS
- PTHL N/A
- IMNN N/A
- Revenue
- PTHL $448,196.00
- IMNN N/A
- Revenue This Year
- PTHL N/A
- IMNN N/A
- Revenue Next Year
- PTHL N/A
- IMNN N/A
- P/E Ratio
- PTHL N/A
- IMNN N/A
- Revenue Growth
- PTHL N/A
- IMNN N/A
- 52 Week Low
- PTHL $0.51
- IMNN $4.83
- 52 Week High
- PTHL $32.00
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- PTHL 30.37
- IMNN 34.44
- Support Level
- PTHL $0.70
- IMNN $5.50
- Resistance Level
- PTHL $1.18
- IMNN $6.96
- Average True Range (ATR)
- PTHL 0.15
- IMNN 0.34
- MACD
- PTHL 0.68
- IMNN 0.05
- Stochastic Oscillator
- PTHL 76.30
- IMNN 17.47
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).